AlphaMark Advisors’s Tvardi Therapeutics TVRD Stock Holding History

AlphaMark Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-40	Closed	-$23K	–	623
2019 Q4	$23K	Sell	40 -1	-2%	-$702	0.01%	260
2019 Q3	$27K	Hold	41	–	–	0.01%	245
2019 Q2	$31K	Hold	41	–	–	0.01%	242
2019 Q1	$29K	Hold	41	–	–	0.01%	232
2018 Q4	$19K	Hold	41	–	–	0.01%	251
2018 Q3	$35K	Hold	41	–	–	0.01%	244
2018 Q2	$28K	Buy	41 +1	+3%	+$508	0.01%	270
2018 Q1	$18K	Hold	40	–	–	0.01%	299
2017 Q4	$18K	Hold	40	–	–	0.01%	296
2017 Q3	$20K	Hold	40	–	–	0.01%	276
2017 Q2	$22K	Hold	40	–	–	0.01%	263
2017 Q1	$26K	Hold	40	–	–	0.01%	241
2016 Q4	$13K	Hold	40	–	–	0.01%	290
2016 Q3	$12K	Buy	+40	New	+$8.67K	0.01%	234

Other funds holding TVRD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AlphaMark Advisors's TVRD Position: Q1 2020 in Review

AlphaMark Advisors sold out of Tvardi Therapeutics (TVRD) in Q1 2020, closing a stake of 40 shares — an estimated $23K sold.

AlphaMark Advisors first reported a position in TVRD in Q3 2016 and held it in 14 quarters. The position peaked at $35K in Q3 2018. 133 funds tracked by Wall St. Rank hold TVRD as of Q1 2020.

AlphaMark Advisors reported no remaining Tvardi Therapeutics position as of Q1 2020 after selling out during the quarter.
AlphaMark Advisors sold 40 Tvardi Therapeutics shares in Q1 2020, an estimated $23K.
AlphaMark Advisors first reported a position in Tvardi Therapeutics in Q3 2016 and held it in 14 quarters.
AlphaMark Advisors's Tvardi Therapeutics position peaked at $35K in Q3 2018.
133 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2020.

Based on AlphaMark Advisors's 13F filing for Q1 2020, filed 24 Apr 2020.